Relmada Therapeutics Stock Earnings Reports

Relmada reported strong operational progress in Q1 2026, centered on NDV-01 (a sustained‑release intravesical gemcitabine/docetaxel) and preparatory work for sepranolone. Key clinical highlights include robust 12‑month Phase 2 data for NDV‑01 (high complete response rates and favorable safety with no grade ≥3 treatment‑related AEs, no progression to muscle‑invasive disease, and no radical cystectomies) and FDA alignment on a two‑pathway registrational Phase 3 RESCUE program (a single‑arm second‑line BCG‑unresponsive study and a randomized adjuvant trial in intermediate‑risk patients). Management expects to initiate the RESCUE program in mid‑2026 and to present the 12‑month Phase 2 data at AUA 2026. IP progress includes a U.S. provisional patent filing that, if issued and extended worldwide, could provide protection into 2047. The company completed a $160M private placement and ended Q1 with $234M cash, which management says funds operations through 2029 and supports completion of Phase 3. Sepranolone preparations are underway with a planned Prader‑Willi syndrome PoC study targeted for mid‑2026. Q1 financials: R&D expense $8.1M, G&A $11.4M, net loss $19.1M ($0.22/share), and net cash used in operating activities $15.1M. Management emphasized execution, site engagement, potentially rapid enrollment driven by strong investigator interest, and the convenience/off‑label positioning of NDV‑01 (office administration in under 5 minutes) as potential advantages for adoption.